secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001104659-25-059687
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus acquires Sage Therapeutics for up to $795M ($12/share including CVR)
-----------------------------------------------------------------------------

- Supernus to acquire Sage via tender offer at $8.50/share cash plus CVR up to $3.50/share, total up to $795M.
- CVR milestones tied to Zurzuvae net sales thresholds ($250M–$375M in U.S. by 2027–2030) and Japan approval.
- Deal expected to close Q3 2025; funded from Supernus's cash; cost synergies up to $200M annually.
- ZURZUVAE (zuranolone) for postpartum depression is the key asset; Supernus records 50% of U.S. net revenue via Biogen collab.
- Transaction unanimously approved by both boards; expected to be significantly accretive in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000110465925059687/0001104659-25-059687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000110465925059687/tm2518064d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-059687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer